首页> 外文OA文献 >Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

【2h】

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

机译：年龄和脆弱对一次每周塞米松，硼替佐米和地塞米松的疗效和耐受性的影响在先前治疗的多发性骨髓瘤中的疗效和耐受性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Holger W. Auner; Maria Gavriatopoulou; Sosana Delimpasi; Maryana Simonova; Ivan Spicka; Ludek Pour; Meletios A. Dimopoulos; Iryna Kriachok; Halyna Pylypenko; Xavier Leleu; Vadim Doronin; Ganna Usenko; Roman Hajek; Reuben Benjamin; Tuphan Kanti Dolai; Dinesh Kumar Sinha; Christopher P. Venner; Mamta Garg; Don Ambrose Stevens; Hang Quach; Sundar Jagannath; Phillipe Moreau; Moshe Levy; Ashraf Badros; Larry D. Anderson; Nizar J. Bahlis; Thierry Facon; Maria Victoria Mateos; Michele Cavo; Yi Chai; Melina Arazy; Jatin Shah; Sharon Shacham; Michael G. Kauffman; Paul G. Richardson; Sebastian Grosicki;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Elderly multiple myeloma (MM) patients, who are generally ineligible for transplantation, have high risks of death and treatment discontinuation, and require a regimen incorporating novel agents that balance safety, tolerability, and efficacy. We evaluated alternating bortezomib-dexamethasone and lenalidomide-dexamethasone treatments administered over a 63-day cycle in transplant-ineligible elderly patients with newly diagnosed MM. Subcutaneous bortezomib 1.3 mg/m2 was administered weekly on Days 1, 8, 15, and 22; oral lenalidomide 15 mg daily on Days 36-56; and oral dexamethasone 20 mg on Days 1, 8, 15, 22, 36, 43, 50, and 57 for 6 cycles. The primary endpoint was the overall response rate. [J] . Yokoyama Akihiro, Kada Akiko, Saito Akiko M., Acta medica Okayama . 2019,第6期

机译：通常不适合移植的老年多发性骨髓瘤（MM）患者具有很高的死亡和中止治疗的风险，因此需要一种方案，该方案应采用能够平衡安全性，耐受性和疗效的新型药物。我们评估了在不适合移植的老年初诊MM患者中，硼替佐米-地塞米松和来那度胺-地塞米松在63天周期内的交替治疗。在第1、8、15和22天每周一次皮下注射硼替佐米1.3 mg / m2;在第36-56天每天口服来那度胺15 mg;在第1、8、15、22、36、43、50和57天，口服地塞米松20 mg，共6个周期。主要终点是总体缓解率。
2. US Budget Impact Model for Selinexor, Bortezomib, and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma [J] . Mike Dolph, Gabriel Tremblay, Hoyee Leong ClinicoEconomics and Outcomes Research . 2021,第a期

机译：美国预算影响模型Selinexor，Bortezomib和地塞米松治疗先前治疗多发性骨髓瘤
3. Efficacy and safety of bortezomib plus dexamethasone therapy for refractory or relapsed multiple myeloma: once-weekly administration of bortezomib may reduce the incidence of gastrointestinal adverse events. [J] . Fukushima T, Nakamura T, Iwao H, Anticancer Research: International Journal of Cancer Research and Treatment . 2011,第6期

机译：硼替佐米联合地塞米松治疗难治性或复发性多发性骨髓瘤的疗效和安全性：每周一次给予硼替佐米可以减少胃肠道不良事件的发生。
4. Proteomic alterations caused by treatment with Bortezomib, Doxorubicin, and Dexamethasone in Myeloma [C] . Dominik Dytfeld, Vadiraja B. Bhat, Malathi Hari, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2009

机译：用髓质族，多柔比星和地塞米松治疗引起的蛋白质组学改变
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. US Budget Impact Model for Selinexor Bortezomib and Dexamethasone for the Treatment of Previously Treated Multiple Myeloma [O] . Mike Dolph, Gabriel Tremblay, Hoyee Leong 2021

机译：塞里宁克斯硼德西布和地塞米松的美国预算影响模型用于治疗先前治疗多发性骨髓瘤
7. Peripheral Neuropathy Symptoms, Pain, and Functioning in Previously Treated Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone [O] . Larysa Sanchez, Xavier Leleu, Jennifer L. Beaumont, 2021

机译：在先前治疗的多发性骨髓瘤患者治疗塞列克斯克斯，硼卓和地塞米松和地塞米松的外周神经病变症状，疼痛和功能

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

著录项

相似文献

相关主题

期刊订阅